Literature DB >> 23471635

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.

Maria G Guzman1, Mayling Alvarez, Scott B Halstead.   

Abstract

Today, dengue viruses are the most prevalent arthropod-borne viruses in the world. Since the 1960s, numerous reports have identified a second heterologous dengue virus (DENV) infection as a principal risk factor for severe dengue disease (dengue hemorrhagic fever/dengue shock syndrome, DHF/DSS). Modifiers of dengue disease response include the specific sequence of two DENV infections, the interval between infections, and contributions from the human host, such as age, ethnicity, chronic illnesses and genetic background. Antibody-dependent enhancement (ADE) of dengue virus infection has been proposed as the early mechanism underlying DHF/DSS. Dengue cross-reactive antibodies raised following a first dengue infection combine with a second infecting virus to form infectious immune complexes that enter Fc-receptor-bearing cells. This results in an increased number of infected cells and increased viral output per cell. At the late illness stage, high levels of cytokines, possibly the result of T cell elimination of infected cells, result in vascular permeability, leading to shock and death. This review is focused on the etiological role of secondary infections (SI) and mechanisms of ADE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23471635     DOI: 10.1007/s00705-013-1645-3

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  251 in total

1.  Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.

Authors:  Rajendra Raut; Kizzmekia S Corbett; Rashika N Tennekoon; Sunil Premawansa; Ananda Wijewickrama; Gayani Premawansa; Piotr Mieczkowski; Claudia Rückert; Gregory D Ebel; Aruna D De Silva; Aravinda M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-05       Impact factor: 11.205

2.  A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.

Authors:  Vanessa V Sarathy; Mellodee White; Li Li; Summer R Gorder; Richard B Pyles; Gerald A Campbell; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  First round of external quality assessment of dengue diagnostics in the WHO Western Pacific Region, 2013.

Authors:  Kwoon Yong Pok; Raynal C Squires; Li Kiang Tan; Tomohiko Takasaki; Sazaly Abubakar; Futoshi Hasebe; Jeffrey Partridge; Chin Kei Lee; Janice Lo; John Aaskov; Lee Ching Ng; Frank Konings
Journal:  Western Pac Surveill Response J       Date:  2015-06-30

Review 4.  Convalescent plasma: new evidence for an old therapeutic tool?

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Liviana Catalano; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

Review 5.  The tortoise or the hare? Impacts of within-host dynamics on transmission success of arthropod-borne viruses.

Authors:  Benjamin M Althouse; Kathryn A Hanley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

6.  Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.

Authors:  Rosa Ramírez; Rosabel Falcón; Alienys Izquierdo; Angélica García; Mayling Alvarez; Ana Beatriz Pérez; Yudira Soto; Mayra Muné; Emiliana Mandarano da Silva; Oney Ortega; Ronaldo Mohana-Borges; María G Guzmán
Journal:  Virus Genes       Date:  2014-05-23       Impact factor: 2.332

Review 7.  Biochemistry and Molecular Biology of Flaviviruses.

Authors:  Nicholas J Barrows; Rafael K Campos; Kuo-Chieh Liao; K Reddisiva Prasanth; Ruben Soto-Acosta; Shih-Chia Yeh; Geraldine Schott-Lerner; Julien Pompon; October M Sessions; Shelton S Bradrick; Mariano A Garcia-Blanco
Journal:  Chem Rev       Date:  2018-04-13       Impact factor: 60.622

Review 8.  Zika virus - reigniting the TORCH.

Authors:  Carolyn B Coyne; Helen M Lazear
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

9.  A Cyclic Phosphoramidate Prodrug of 2'-Deoxy-2'-Fluoro-2'-C-Methylguanosine for the Treatment of Dengue Virus Infection.

Authors:  Ratna Karuna; Fumiaki Yokokawa; Keshi Wang; Jin Zhang; Haoying Xu; Gang Wang; Mei Ding; Wai Ling Chan; Nahdiyah Abdul Ghafar; Andrea Leonardi; Cheah Chen Seh; Peck Gee Seah; Wei Liu; Rao P S Srinivasa; Siew Pheng Lim; Suresh B Lakshminarayana; Ellie Growcott; Sreehari Babu; Martijn Fenaux; Weidong Zhong; Feng Gu; Pei-Yong Shi; Francesca Blasco; Yen-Liang Chen
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

10.  Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses.

Authors:  Audrey Stéphanie Richard; Adam Zhang; Sun-Jin Park; Michael Farzan; Min Zong; Hyeryun Choe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.